We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

83 hedge funds and large institutions have $539M invested in ArriVent BioPharma in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 22

27% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 11

4% more funds holding

Funds holding: 80 → 83 (+3)

1% more ownership

Funds ownership: 84.47% → 85.46% (+1%)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

29% less capital invested

Capital invested by funds: $757M → $539M (-$218M)

Holders
83
Holders Change
+3
Holders Change %
+3.75%
% of All Funds
1.11%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.07%
New
14
Increased
29
Reduced
22
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IAM
Infinitum Asset Management
Florida
+$10.3M
2
NHAS
Novo Holdings A/S
Denmark
+$8.6M
3
UBS Group
UBS Group
Switzerland
+$3.17M
4
Millennium Management
Millennium Management
New York
+$2.58M
5
SCM
Suvretta Capital Management
New York
+$2.24M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$15.6M
2
Goldman Sachs
Goldman Sachs
New York
-$3.19M
3
State Street
State Street
Massachusetts
-$1.13M
4
Morgan Stanley
Morgan Stanley
New York
-$652K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$548K
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$765K +$1.01M +41,381 New
Barclays
27
Barclays
United Kingdom
$750K -$316K -12,916 -24%
RhumbLine Advisers
28
RhumbLine Advisers
Massachusetts
$687K +$11.1K +453 +1%
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$680K +$464K +18,955 +106%
Marshall Wace
30
Marshall Wace
United Kingdom
$663K +$877K +35,851 New
Citigroup
31
Citigroup
New York
$632K +$1.18K +48 +0.1%
Bank of America
32
Bank of America
North Carolina
$541K -$398K -16,259 -36%
AllianceBernstein
33
AllianceBernstein
Tennessee
$521K – – –
Swiss National Bank
34
Swiss National Bank
Switzerland
$488K – – –
AA
35
ALPS Advisors
Colorado
$465K -$51K -2,085 -8%
Deutsche Bank
36
Deutsche Bank
Germany
$429K -$23.3K -953 -4%
SG Americas Securities
37
SG Americas Securities
New York
$419K +$266K +10,873 +92%
ECM
38
ExodusPoint Capital Management
New York
$412K +$545K +22,268 New
Squarepoint
39
Squarepoint
New York
$341K +$451K +18,426 New
IIM
40
INTECH Investment Management
Florida
$334K +$80K +3,271 +22%
Two Sigma Advisers
41
Two Sigma Advisers
New York
$333K +$441K +18,000 New
Mirae Asset Global ETFs Holdings
42
Mirae Asset Global ETFs Holdings
Hong Kong
$325K +$10.6K +432 +3%
Rafferty Asset Management
43
Rafferty Asset Management
New York
$322K -$242K -9,890 -36%
MIM
44
MetLife Investment Management
New Jersey
$316K -$8.56K -350 -2%
JP Morgan Chase
45
JP Morgan Chase
New York
$302K +$15.8K +644 +4%
Tudor Investment Corp
46
Tudor Investment Corp
Connecticut
$283K +$374K +15,293 New
Invesco
47
Invesco
Georgia
$280K -$5.12K -209 -1%
Wells Fargo
48
Wells Fargo
California
$274K +$7.98K +326 +2%
DTL
49
Dynamic Technology Lab
Singapore
$266K +$352K +14,379 New
CF
50
Corebridge Financial
Texas
$255K -$4.99K -204 -1%
1
2
3 4

AVBP Hedge Fund Activity: Q1 2025 in Review

83 of the 7,460 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q1 2025, worth a combined $539M — down 29% from $757M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new AVBP positions and 11 closed out — a net gain of 3 holders — while 29 added to existing stakes and 22 trimmed.

The largest buyer was Infinitum Asset Management, adding an estimated $10.3M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $15.6M sold.

  • 83 institutional investors held ArriVent BioPharma (AVBP) as of Q1 2025, up from 80 in Q4 2024.
  • Funds reported $539M of ArriVent BioPharma stock for Q1 2025, down 29% quarter-over-quarter.
  • 14 funds opened new ArriVent BioPharma positions in Q1 2025 and 11 closed out, a net change of +3 holders.
  • The largest ArriVent BioPharma buyer in Q1 2025 was Infinitum Asset Management, an estimated $10.3M added.
  • The largest ArriVent BioPharma seller in Q1 2025 was Cormorant Asset Management, an estimated $15.6M sold.

Based on aggregated 13F filings for Q1 2025.